![]() |
Leukemia |
Free Subscription
1 Am J Clin Oncol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Leukemia is free of charge.
Global Trends in Childhood Acute Lymphoblastic Leukemia Burden and Quality of
Care Inequalities Across Regions, 1990 to 2021: A Systematic Analysis Using
Global Burden of Disease Study 2021 Data.
Am J Clin Oncol. 2025 May 19. doi: 10.1097/COC.0000000000001210.
PubMed
Abstract available
A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory
Acute Myeloid Leukemia.
Am J Hematol. 2025 May 22. doi: 10.1002/ajh.27723.
PubMed
Abstract available
Epidemiologic sequential analysis of pure red blood cell aplasia and T-cell large
granular lymphocyte leukemia in Korea.
Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06406.
PubMed
Abstract available
Selective efficacy of venetoclax in unfit patients with acute myeloid leukemia
with myelodysplasia-related gene mutations under low-intensity therapy.
Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06399.
PubMed
Abstract available
Molecular analysis of T-cell Acute Lymphoblastic Leukemia arising after Essential
Thrombocythemia foreshadows a distinct clonal route for lymphoid blast crisis in
Philadelphia-negative chronic myeloproliferative neoplasm: a case report with
literary r
Ann Hematol. 2025 May 22. doi: 10.1007/s00277-025-06404.
PubMed
Abstract available
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly
diagnosed and relapsed/refractory acute myeloid leukemia: results of a single
center study.
Ann Hematol. 2025 May 20. doi: 10.1007/s00277-025-06389.
PubMed
Abstract available
Classic hairy cell leukemia and concomitant smoldering myeloma.
Blood. 2025;145:2533.
PubMed
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage
ALL: the GIMEMA LAL2317 phase 2 study.
Blood. 2025;145:2447-2459.
PubMed
Abstract available
Venetoclax and hypomethylating agents versus induction chemotherapy for newly
diagnosed acute myeloid leukemia patients: a systematic review and meta-analysis.
BMC Cancer. 2025;25:894.
PubMed
Abstract available
Emerging roles of ADAM6 and PRSS1 as novel diagnostic/prognostic biomarkers for
acute lymphoblastic and myeloid leukemia in adults.
BMC Cancer. 2025;25:884.
PubMed
Abstract available
A clinical solution for tracking clonal evolution of acute myeloid leukemia after
allogeneic transplantation using bulk next generation sequencing.
Bone Marrow Transplant. 2025 May 16. doi: 10.1038/s41409-025-02602.
PubMed
Abstract available
N-acetyl-L-cysteine promoted hematopoietic recovery in patients with acute
myeloid leukemia after complete remission--A pilot study.
Cancer Lett. 2025 May 20:217812. doi: 10.1016/j.canlet.2025.217812.
PubMed
Abstract available
Toxicity, progression-free survival, and quality of life of patients treated with
zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in
relapsed or refractory chronic lymphocytic leukemia.
Leuk Lymphoma. 2025 May 23:1-9. doi: 10.1080/10428194.2025.2506501.
PubMed
Abstract available
Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia
chromosome negative acute lymphoblastic leukemia in adults >/=40 years old.
Leuk Lymphoma. 2025 May 21:1-5. doi: 10.1080/10428194.2025.2506003.
PubMed
AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor
immune microenvironment in acute myeloid leukemia.
Leuk Lymphoma. 2025 May 19:1-15. doi: 10.1080/10428194.2025.2504161.
PubMed
Abstract available
Central nervous system relapse of core-binding factor acute myeloid leukemia.
Leuk Lymphoma. 2025 May 19:1-4. doi: 10.1080/10428194.2025.2506505.
PubMed
Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions:
Real-life study from the French CML group Fi-LMC.
Leuk Res. 2025;154:107716.
PubMed
Abstract available
Targeting lipid metabolism in acute myeloid leukemia: biological insights and
therapeutic opportunities.
Leukemia. 2025 May 22. doi: 10.1038/s41375-025-02645.
PubMed
Abstract available
Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay
in vivo.
Leukemia. 2025 May 20. doi: 10.1038/s41375-025-02626.
PubMed
Abstract available
Targeting KPNB1 suppresses AML cells by inhibiting HMGB2 nuclear import.
Oncogene. 2025;44:1646-1661.
PubMed
Abstract available
Microbiome and pediatric leukemia, diabetes, and allergies: Systematic review and
meta-analysis.
PLoS One. 2025;20:e0324167.
PubMed
Abstract available
An efficient leukemia prediction method using machine learning and deep learning
with selected features.
PLoS One. 2025;20:e0320669.
PubMed
Abstract available
Mutant IDH1 cooperates with NPM1c or FLT3(ITD) to drive distinct myeloid diseases
and molecular outcomes.
Proc Natl Acad Sci U S A. 2025;122:e2415779122.
PubMed
Abstract available
Thank you for your interest in scientific medicine.